BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33021971)

  • 21. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
    Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
    Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM; Bagg A
    Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A
    Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
    Romzova M; Smitalova D; Hynst J; Tom N; Loja T; Herudkova Z; Jurcek T; Stejskal L; Zackova D; Mayer J; Racil Z; Culen M
    Br J Haematol; 2021 Aug; 194(3):604-612. PubMed ID: 34212373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Case Report of
    Ali EAH; Al-Akiki S; Yassin MA
    Case Rep Oncol; 2021; 14(1):690-694. PubMed ID: 34054462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
    Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.
    Cross NC; Daley GQ; Green AR; Hughes TP; Jamieson C; Manley P; Mughal T; Perrotti D; Radich J; Skoda R; Soverini S; Vainchenker W; Verstovsek S; Villeval JL; Goldman JM
    Leukemia; 2008 Nov; 22(11):1975-89. PubMed ID: 19002192
    [No Abstract]   [Full Text] [Related]  

  • 28. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
    Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
    Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary chronic myeloid leukemia in a patient with CALR and ASXL1-mutated primary myelofibrosis.
    Sobieralski P; Bieniaszewska M; Leszczyńska A; Żuk M; Wasąg B; Zaucha JM
    Int J Hematol; 2022 Sep; 116(3):442-445. PubMed ID: 35429330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
    Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation.
    Deng Q; Wang E; Wu X; Cheng Q; Liu J; Li X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 45(7):874-880. PubMed ID: 32879093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
    Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
    Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
    Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
    Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
    Xu W; Chen B; Tong X
    Int J Hematol; 2014 Jan; 99(1):87-90. PubMed ID: 24293258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
    Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Jak-2 positive myeloproliferative neoplasms.
    Muxí PJ; Oliver AC
    Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.